Christopher A. Viehbacher joined Biogen as President and Chief Executive Officer and a member of the Board of Directors in November 2022.

Viehbacher has extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies and has a passion for advancing science for the benefit of patients and public health.

After 20 years with GlaxoSmithKline, he served as global CEO of Sanofi for six years. Under Viehbacher’s leadership, Sanofi strengthened and diversified its R&D pipeline and delivered significant value to shareholders.

More recently, Viehbacher and Ernesto Bertarelli co-founded Gurnet Point Capital, a Cambridge-based healthcare investment fund, which has led to the creation and continuing development of many innovative companies. He has also chaired or been a member of the board of a number of entrepreneurial companies in biotechnology. Viehbacher has always been a strong advocate for innovation and public health. He has received a number of awards including the Légion d’Honneur from France.

He graduated from Queen’s University in Kingston, Ontario, Canada. He is a certified public accountant, and he speaks French, German and English.